GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Current Ratio

Peak Bio (Peak Bio) Current Ratio : 0.08 (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Peak Bio Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Peak Bio's current ratio for the quarter that ended in Jun. 2023 was 0.08.

Peak Bio has a current ratio of 0.08. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Peak Bio has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Peak Bio's Current Ratio or its related term are showing as below:

PKBO' s Current Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.14   Max: 0.3
Current: 0.08

During the past 2 years, Peak Bio's highest Current Ratio was 0.30. The lowest was 0.07. And the median was 0.14.

PKBO's Current Ratio is ranked worse than
97.05% of 1557 companies
in the Biotechnology industry
Industry Median: 3.73 vs PKBO: 0.08

Peak Bio Current Ratio Historical Data

The historical data trend for Peak Bio's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peak Bio Current Ratio Chart

Peak Bio Annual Data
Trend Dec21 Dec22
Current Ratio
0.16 0.30

Peak Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Current Ratio Get a 7-Day Free Trial - 0.07 0.30 0.14 0.08

Competitive Comparison of Peak Bio's Current Ratio

For the Biotechnology subindustry, Peak Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peak Bio's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peak Bio's Current Ratio distribution charts can be found below:

* The bar in red indicates where Peak Bio's Current Ratio falls into.



Peak Bio Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Peak Bio's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=3.231/10.801
=0.30

Peak Bio's Current Ratio for the quarter that ended in Jun. 2023 is calculated as

Current Ratio (Q: Jun. 2023 )=Total Current Assets (Q: Jun. 2023 )/Total Current Liabilities (Q: Jun. 2023 )
=1.514/18.013
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peak Bio  (OTCPK:PKBO) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Peak Bio Current Ratio Related Terms

Thank you for viewing the detailed overview of Peak Bio's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Peak Bio (Peak Bio) Business Description

Traded in Other Exchanges
N/A
Address
4900 Hopyard Road, Suite 100, Pleasanton, CA, USA, 94588
Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
Executives
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Michael R. Friedman director 245 E. 58TH STREET, APT #15B, NEW YORK NY 10022
Peter David Mccabe officer: General Counsel 584 CASTRO STREET, #882, SAN FRANCISCO CA 94114
Sbi Kis 2016-1 Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO GANGNAM, SEOUL M5 00000
2014 Kif-sbi It Investment Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
2019 Sbi Job Creation Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Investment Korea Co., Ltd. 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Healthcare Fund I 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Cross-border Advantage Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Bio Fund 1 Ikbc-sbi 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Gateway Fund 1 Global 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Satyajit Kumar Mitra officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Stephen J Lamond director, officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
David I. Rosenberg director C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019